https://orcid.org/0000-0001-9505-4340
References
- Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51:883–890. doi:10.1111/j.1528-1167.2009.02481.x
- Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51:1236–1241. doi:10.1111/j.1528-1167.2009.02474.x
- Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia. 2004;45:171–178. doi:10.1111/j.0013-9580.2004.14103.x
- Beghi E. Addressing the burden of epilepsy: many unmet needs. Pharmacol Res. 2016;107:79–84. doi:10.1016/j.phrs.2016.03.003
- Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9:68–82. doi:10.1038/nrd2997
- Perucca E. The pharmacological treatment of epilepsy: recent advances and future perspectives. Acta Epileptologica. 2021;3:22. doi:10.1186/s42494-021-00055-z
- Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med. 2011;365:919–926. doi:10.1056/NEJMra1004418
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319. doi:10.1056/NEJM200002033420503
- Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure. 2002;11:77–84. doi:10.1053/seiz.2002.0593
- Engel J, Wiebe S, French J, et al. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology in Association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology. 2003;60:538–547. doi:10.1212/01.wnl.0000055086.35806.2d
- Allers K, Essue BM, Hackett ML, et al. The economic impact of epilepsy: a systematic review. BMC Neurol. 2015;15:245. doi:10.1186/s12883-015-0494-y
- Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 1994;18:249–260. doi:10.1016/0920-1211(94)90045-0
- An S, Malhotra K, Dilley C, et al. Predicting drug-resistant epilepsy - a machine learning approach based on administrative claims data. Epilepsy Behav. 2018;89:118–125. doi:10.1016/j.yebeh.2018.10.013
- Franchi C, Giussani G, Messina P, et al. Validation of healthcare administrative data for the diagnosis of epilepsy. J Epidemiol Community Health. 2013;67:1019–1024. doi:10.1136/jech-2013-202528
- Keezer MR, Sisodiya SM, Sander JW, et al. Comorbidities of epilepsy: current concepts and future perspectives. Lancet. 2016;15:106–115. doi:10.1016/S1474-4422(15)00225-2
- Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia. 2012;53:1282–1293. doi:10.1111/j.1528-1167.2012.03528.x
- LaFrance WC, Kanner AM, Hermann B. Psychiatric comorbidities in epilepsy. Int Rev Neurobiol. 2008;83:347–383.
- Wilner AN, Sharma BK, Soucy A, Thompson A, Krueger A. Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010. Epilepsy Behav. 2014;32:15–20. doi:10.1016/j.yebeh.2013.12.032
- Park KM, Kim SE, Lee BI. Antiepileptic drug therapy in patients with drug-resistant epilepsy. J Epilepsy Res. 2019;9:14–26. doi:10.14581/jer.19002
- Owczarek K, Jedrzejczak J. Ekonomiczne aspekty padaczek opornych na leczenie [Economic aspects of drug-resistant epilepsy]. Neurol Neurochir Pol. 2001;35:309–318.
- Porter R. Economic factors in the development of new antiepileptic drugs. Adv Neurol. 1998;76:239–244.